X
9.21
0.08 (0.88%)
| Penutupan Terdahulu | 9.13 |
| Buka | 9.29 |
| Jumlah Dagangan | 1,719,404 |
| Purata Dagangan (3B) | 2,536,278 |
| Modal Pasaran | 1,487,234,176 |
| Harga / Pendapatan (P/E Ke hadapan) | 22.17 |
| Harga / Jualan (P/S) | 3.82 |
| Harga / Buku (P/B) | 3.34 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -20.25% |
| Margin Operasi (TTM) | -5.14% |
| EPS Cair (TTM) | -0.290 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 47.90% |
| Nisbah Semasa (MRQ) | 1.72 |
| Aliran Tunai Operasi (OCF TTM) | -26.71 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.90 M |
| Pulangan Atas Aset (ROA TTM) | -3.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Xeris Biopharma Holdings, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.7
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.70 |
|
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.19% |
| % Dimiliki oleh Institusi | 54.46% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 18.00 (Oppenheimer, 95.44%) | Beli |
| Median | 10.00 (8.58%) | |
| Rendah | 8.00 (Piper Sandler, -13.14%) | Pegang |
| Purata | 12.00 (30.29%) | |
| Jumlah | 2 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 7.43 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Nov 2025 | 10.00 (8.58%) | Beli | 7.43 |
| Oppenheimer | 07 Nov 2025 | 18.00 (95.44%) | Beli | 7.43 |
| 29 Oct 2025 | 18.00 (95.44%) | Beli | 9.62 | |
| Piper Sandler | 07 Nov 2025 | 8.00 (-13.14%) | Pegang | 7.43 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HECHT BETH | - | 6.96 | -16,667 | -116,002 |
| Jumlah Keseluruhan Kuantiti Bersih | -16,667 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -116,002 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 6.96 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HECHT BETH | Pegawai | 01 Dec 2025 | Jual automatik (-) | 16,667 | 6.96 | 116,002 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 01 Dec 2025 | Pengumuman | Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application |
| 06 Nov 2025 | Pengumuman | Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 |
| 23 Oct 2025 | Pengumuman | Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025 |
| 03 Oct 2025 | Pengumuman | Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |